60 Racial Disparities in Hospitalization Outcomes Among Women With Metastatic Breast Cancer in the United States by Palliative Care Utilization

Publication
Article
Miami Breast Cancer Conference® Abstracts Supplement41st Annual Miami Breast Cancer Conference® - Abstracts
Volume 38
Issue 4
Pages: 74-75

Background

While studies have reported that members of racial and minority populations hospitalized with metastatic breast cancer (MBC) have lower palliative care use than non-Hispanic White women, disparities in hospital-associated outcomes among inpatients have not been explored in this population. We examined the racial disparities in hospitalization outcomes among adult women with a diagnosis of MBC, stratified by receipt of palliative care.

Methods

Retrospective cohort analyses were conducted using the Agency for Healthcare Research and Quality (AHRQ)–sponsored Healthcare Cost and Utilization Project, National Inpatient Sample (HCUP–NIS) database from 2016 to 2020. Multivariable logistic and linear regression models were used to examine the association between race/ethnicity and in-hospital mortality, length of stay, and total hospital charges. Multinomial logistic regression models were used to evaluate the association between race/ethnicity and discharge disposition. Stratified analyses were conducted by palliative care use. Results were reported as adjusted odds ratios (AOR).

Results

Racial Disparities in Hospitalization Outcomes Among Women With Metastatic Breast Cancer by Palliative Care Receipt

Racial Disparities in Hospitalization Outcomes Among Women With Metastatic Breast Cancer by Palliative Care Receipt

Racial Disparities in Hospitalization Outcomes Among Women With Metastatic Breast Cancer by Palliative Care Receipt (cont.)

Racial Disparities in Hospitalization Outcomes Among Women With Metastatic Breast Cancer by Palliative Care Receipt (cont.)

In the adjusted analyses, Black (AOR, 1.25; 95% CI, 1.16-1.34), Hispanic (AOR, 1.12; 95% CI, 1.01-1.23), and other (AOR, 1.26; 95% CI, 1.12-1.40) MBC patients had higher in-hospital mortality compared to the White patients. After stratifying by palliative care use, Black women who received palliative care had similar odds (AOR, 1.08; 95% CI, 0.97-1.20) of in-hospital mortality while those without palliative care use had 46% higher odds (95% CI, 1.30-1.64) of mortality when compared to White women. Black women were more likely (AOR, 1.18; 95% CI, 1.13-1.23) to have a length of stay greater than 5 days compared to 5 days or less relative to White women. Furthermore, Black, Hispanic, and other women had higher total hospital charges when compared with patients who are White. While women who were Black had similar odds (AOR, 0.98; 95% CI, 0.92-1.04) of being discharged to a short-term/skilled nursing facility vs routine discharge compared with women who were White, women who were Black who received palliative care had 19% (95% CI, 0.70-0.95) lower odds of being discharged to a facility. Hispanic and other MBC patients were less likely to be discharged to a facility relative to routine discharge when compared with women who were White.

Conclusions

Despite the improvement in palliative care use over the years, members of racial minority populations continue to have poorer outcomes. However, patients who are Black with MBC who received palliative care had similar in-hospital mortality and were less likely to be discharged to a facility when compared with their White counterparts. Our findings emphasize the importance of palliative care use among MBC patients and highlight the need to continue to raise awareness of its benefits, especially in minority populations. Further studies are needed to explore ways to narrow the gap in existing disparities and to test these interventions on care metrics and patient outcomes.

Articles in this issue

28 Enhancing the Interpretation of Real-World Quality of Life (QoL) in Patients With Hormone Receptor– Positive/Human Epidermal Growth Factor Receptor 2–Negative (HR+/HER2-) Advanced Breast Cancer (ABC) Enrolled in the POLARIS Trial
28 Enhancing the Interpretation of Real-World Quality of Life (QoL) in Patients With Hormone Receptor– Positive/Human Epidermal Growth Factor Receptor 2–Negative (HR+/HER2-) Advanced Breast Cancer (ABC) Enrolled in the POLARIS Trial
29 ELEVATE: A Phase 1b/2, Open-Label, Umbrella Study Evaluating Elacestrant in Various Combinations in Patients (pts) With Estrogen Receptor–Positive (ER+), HER2-Negative (HER2–) Locally Advanced or Metastatic Breast Cancer (mBC)
29 ELEVATE: A Phase 1b/2, Open-Label, Umbrella Study Evaluating Elacestrant in Various Combinations in Patients (pts) With Estrogen Receptor–Positive (ER+), HER2-Negative (HER2–) Locally Advanced or Metastatic Breast Cancer (mBC)
30 Datopotamab Deruxtecan (Dato-DXd) vs Chemotherapy in Previously-Treated Inoperable or Metastatic Hormone Receptor–Positive, HER2-Negative (HR+/HER2–) Breast Cancer (BC): Primary Results From the Randomised Phase 3 TROPION-Breast01 Trial
30 Datopotamab Deruxtecan (Dato-DXd) vs Chemotherapy in Previously-Treated Inoperable or Metastatic Hormone Receptor–Positive, HER2-Negative (HR+/HER2–) Breast Cancer (BC): Primary Results From the Randomised Phase 3 TROPION-Breast01 Trial
31 Adjuvant Abemaciclib Plus Endocrine Therapy for HR+, HER2–, High-Risk Early Breast Cancer: Results From a Preplanned MonarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes
31 Adjuvant Abemaciclib Plus Endocrine Therapy for HR+, HER2–, High-Risk Early Breast Cancer: Results From a Preplanned MonarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes
32 Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy Followed by Adjuvant Pembrolizumab or Placebo for Early-Stage Triple- Negative Breast Cancer: Updated Event-Free Survival Results From the Phase 3 KEYNOTE-522 Study
32 Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy Followed by Adjuvant Pembrolizumab or Placebo for Early-Stage Triple- Negative Breast Cancer: Updated Event-Free Survival Results From the Phase 3 KEYNOTE-522 Study
33 MammaPrint® and BluePrint® Predict Anthracycline Chemosensitivity in Patients With HR+HER2– Early-Stage Breast Cancer Enrolled in FLEX
33 MammaPrint® and BluePrint® Predict Anthracycline Chemosensitivity in Patients With HR+HER2– Early-Stage Breast Cancer Enrolled in FLEX
34 How Mobile Computing Devices Offer Support for Classic and Molecular Multidisciplinary and Tumor Boards
34 How Mobile Computing Devices Offer Support for Classic and Molecular Multidisciplinary and Tumor Boards
35 Impact of Comorbidities on Real-World (rw) Clinical Outcomes of Patients (pts) With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2–Negative (HR+/HER2–) Advanced Breast Cancer (ABC) Treated With Palbociclib (PAL) and Enrolled in POLARIS
35 Impact of Comorbidities on Real-World (rw) Clinical Outcomes of Patients (pts) With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2–Negative (HR+/HER2–) Advanced Breast Cancer (ABC) Treated With Palbociclib (PAL) and Enrolled in POLARIS
36 MONARCH 3: Final Overall Survival Results of Abemaciclib Plus a Nonsteroidal Aromatase Inhibitor as First-Line Therapy for HR+/HER2– Advanced Breast Cancer
36 MONARCH 3: Final Overall Survival Results of Abemaciclib Plus a Nonsteroidal Aromatase Inhibitor as First-Line Therapy for HR+/HER2– Advanced Breast Cancer
37 Estimating the Direct and Indirect Resource Burden of Treatment Management With Current Standard of Care or Elacestrant for ER+, HER2–, ESR1-Mutated Advanced or Metastatic Breast Cancer Patients: A Population- Level Provider Model
37 Estimating the Direct and Indirect Resource Burden of Treatment Management With Current Standard of Care or Elacestrant for ER+, HER2–, ESR1-Mutated Advanced or Metastatic Breast Cancer Patients: A Population- Level Provider Model
38 Influence of Race on Attainment of Textbook Oncologic Outcome Following Modified Radical Mastectomy for Breast Cancer
38 Influence of Race on Attainment of Textbook Oncologic Outcome Following Modified Radical Mastectomy for Breast Cancer
39 The Influence of Reconstruction Type on Outcomes in Women Undergoing Mastectomy With Immediate Reconstruction:  A Nationwide Study
39 The Influence of Reconstruction Type on Outcomes in Women Undergoing Mastectomy With Immediate Reconstruction: A Nationwide Study
40 Ethnic Disparities in Complication Rates and Outcomes  of Nipple-Sparing Mastectomy:  A Comprehensive Analysis
40 Ethnic Disparities in Complication Rates and Outcomes of Nipple-Sparing Mastectomy: A Comprehensive Analysis
41 A Case Series of Sarcomas
41 A Case Series of Sarcomas
42 Transitional Lymphedema: Understanding the Temporal Dynamics Post-Axillary Surgery
42 Transitional Lymphedema: Understanding the Temporal Dynamics Post-Axillary Surgery
Recent Videos
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Carey Anders, MD, an expert on breast cancer
Related Content